Aktiesnakken — Oktober 2010
-
-
interessant - NGAL som markør i galde, det var en af punkterne fra Alere, i indsigelsen, at BP patent dækkede alle legemsvæsker bl. galde/Bi
-
-
heri er der en 13.9 fordobling af ngal i galdevæsken, ved kræftdiagnose
-
som jeg umiddelbart forstår det, læser lige endnu engang..
-
Alere skrev i indsigelsen imod BioPorto at de fandt det upassende at Bioportos patent dækkede alle legemsvæsker, bl.a. galde og tårer var næ
-
nævnt
-
-
galde....perfekt....
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind